在跨国药企的竞争中,“药王”争霸已然成为一种常态,百亿美元的年销售额已成为进入全球重磅药物榜单的门槛。在2024年全球跨国药企的财报中,最引人注目的当数默沙东的K药与诺和诺德的司美格鲁肽之间的“药王”争霸战。最终,K药以微弱优势胜出,司美格鲁肽惜败。K药如今正值当打之年,2024年创造了新的销售纪录,以18%的增长速度创收294.82亿美元,其销售额约占默沙东全年总营收的46%。默沙东2024年总...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.